Clinical Trial Update: Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders [Phase 1]

View source ↗

Summary

Phase 1 study assessing decitabine with FR901228 (romidepsin) in patients with relapsed or refractory leukemia, myelodysplastic syndromes, and myeloproliferativ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms

Drugs mentioned

• Dacogen (decitabine)
• Istodax (romidepsin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chronic Myeloproliferative Disorders, Leukemia | Phase 1 | Status: COMPLETED